Human Siglec-1/CD169 Antibody
R&D Systems, part of Bio-Techne | Catalog # MAB5197
Recombinant Monoclonal Antibody.
Conjugate
Catalog #
Key Product Details
Validated by
Biological Validation
Species Reactivity
Validated:
Human
Applications
CyTOF-ready, Flow Cytometry
Label
Unconjugated
Antibody Source
Recombinant Monoclonal Mouse IgG1 Clone # 908102
Product Summary for Human Siglec-1/CD169 Antibody
Immunogen
Mouse myeloma cell line NS0-derived recombinant human Siglec-1/CD169
Ser20-Gln1641
Accession # Q9BZZ2
Ser20-Gln1641
Accession # Q9BZZ2
Specificity
Detects human Siglec-1/CD169 in direct ELISAs.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Scientific Data Images for Human Siglec-1/CD169 Antibody
Detection of Siglec-1/CD169 in Human PBMCs by Flow Cytometry.
Human peripheral blood mononuclear cells (PBMCs) either (A) untreated or (B) treated with 5 ng/mL Recombinant Human IFN-a (Catalog # 11100-1) overnight were stained with Mouse Anti-Human Siglec-1/CD169 Monoclonal Antibody (Catalog # MAB5197) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B) and Mouse Anti-Human CD14 PE-conjugated Monoclonal Antibody (Catalog # FAB3832P). Quadrant markers were set based on control antibody staining (Catalog # MAB002).Applications for Human Siglec-1/CD169 Antibody
Application
Recommended Usage
CyTOF-ready
Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
Flow Cytometry
0.25 µg/mL
Sample: Human peripheral blood mononuclear cells (PBMCs) treated with Recombinant Human IFN‑a (Catalog # 11100-1)
Sample: Human peripheral blood mononuclear cells (PBMCs) treated with Recombinant Human IFN‑a (Catalog # 11100-1)
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from cell culture supernatant
Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: Siglec-1/CD169
V‑set domain followed by varying numbers of Ig-like C2-set domains (1, 2). Human Siglec-1, also known as sialoadhesin and CD169, is a 175-185 kDa glycoprotein. It contains a 1622 amino acid (aa) extracellular domain (ECD) with one Ig-like V‑set domain and 16 Ig-like C2-set domains, a 21 aa transmembrane segment, and a 44 aa cytoplasmic domain (3). Within the ECD, human Siglec-1 shares approximately 70% aa sequence identity with mouse and rat Siglec-1. Alternate splicing generates a potentially soluble form of the ECD, and a second isoform with a substituted cytoplasmic domain. Siglec-1 expression is restricted to lymph node and splenic macrophages, plus some tissue macrophages (3). The adhesive function of Siglec-1 is supported by the N-terminal Ig-like domain which shows a selectivity for alpha2,3‑linked sialic acid residues (3‑5). Siglec-1 binds a number of sialylated molecules including the mannose receptor, MGL1, MUC1, PSGL-1, and different glycoforms of CD43 (6‑9). Its binding capacity can be masked by endogenous sialylated molecules (10, 11). The sialylated and sulfated N-linked carbohydrates that modify Siglec-1 itself are required for ligand binding (6, 7). Siglec-1 is expressed on dendritic cells following rhinovirus exposure, and these DC promote T cell anergy (12). It is also induced on circulating monocytes during systemic sclerosis and HIV-1 infection (13‑15). Siglec-1 can trap HIV-1 particles for trans infection of permissive cells (14).
References
- Varki, A. and T. Angata (2006) Glycobiology 16:1R.
- Crocker, P.R. et al. (2007) Nat. Rev. Immunol. 7:255.
- Hartnell, A. et al. (2001) Blood 97:288.
- Nath, D. et al. (1995) J. Biol. Chem. 270:26184.
- Crocker, P.R. et al. (1991) EMBO J. 10:1661.
- Martinez-Pomares, L. et al. (1999) J. Biol. Chem. 274:35211.
- Kumamoto, Y. et al. (2004) J. Biol. Chem. 279:49274.
- Nath, D. et al. (1999) Immunology 98:213.
- van den Berg, T.K. et al. (2001) J. Immunol. 166:3637.
- Nakamura, K. et al. (2002) Glycobiology 12:209.
- Barnes, Y.C. et al. (1999) Blood 93:1245.
- Kirchberger, S. et al. (2005) J. Immunol. 175:1145.
- York, M.R. et al. (2007) Arthritis Rheum. 56:1010.
- Rempel, H. et al. (2008) PloS ONE 3:e1967.
- van der Kuyl, A.C. et al. (2007) Plos ONE 2:e257.
Long Name
Sialic Acid Binding Ig-like Lectin 1
Alternate Names
CD169, Siglec1
Gene Symbol
SIGLEC1
UniProt
Additional Siglec-1/CD169 Products
Product Documents for Human Siglec-1/CD169 Antibody
Product Specific Notices for Human Siglec-1/CD169 Antibody
For research use only
Loading...
Loading...
Loading...
Loading...
Loading...